{"filing":{"accession_number":"0001193125-26-345753","cik":"0001840233","ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"xlo-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526345753/xlo-20260812.htm"},"events":[{"id":27044,"run_id":24614,"accession_number":"0001193125-26-345753","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including collaboration and license revenue of $18.7 million, R\u0026D expenses of $14.6 million, G\u0026A expenses of $7.6 million, and a net loss of $6.4 million for the quarter, along with condensed consolidated balance sheets and statements of operations. The disclosure is material as it provides investors with the company's quarterly financial performance and cash runway guidance into Q1 2028.","company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28403,"accession_number":"0001193125-26-345753","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including collaboration and license revenue of $18.7 million, R\u0026D expenses of $14.6 million, G\u0026A expenses of $7.6 million, and a net loss of $6.4 million for the quarter, along with condensed consolidated balance sheets and statements of operations. The disclosure is material as it provides investors with the company's quarterly financial performance and cash runway guidance into Q1 2028.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:36:39.580823+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28403,"accession_number":"0001193125-26-345753","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including collaboration and license revenue of $18.7 million, R\u0026D expenses of $14.6 million, G\u0026A expenses of $7.6 million, and a net loss of $6.4 million for the quarter, along with condensed consolidated balance sheets and statements of operations. The disclosure is material as it provides investors with the company's quarterly financial performance and cash runway guidance into Q1 2028.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:36:39.580823+00:00","company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","filing_date":"2026-08-12"}]}